Examining the economic costs related to lifestyle and pharmacological interventions in youth with Type 2 diabetes

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 6, Issue 3, 2006, Pages 315-324

  Songer, Thomas ^a   Glazner, Judith ^b   Coombs, Laura P ^c   Cuttler, Leona ^d   Daniel, Mary ^e   Estrada, Silvia ^f   Klingensmith, Georgeanna ^g   Kriska, Andrea ^a   Laffel, Lori ^h   Zhang, Ping ⁱ  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e Kutak Rock LLP   (United States)

^f CHILDREN S HOSPITAL LOS ANGELES   (United States)

^g UNIVERSITY OF COLORADO DENVER   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

Author keywords

Clinical trial; Cost; Cost effectiveness analysis; Diet; Exercise; Obesity; Type 2 diabetes mellitus

Indexed keywords

INSULIN; METFORMIN; METFORMIN PLUS ROSIGLITAZONE;

ADOLESCENT DISEASE; AGE; BEHAVIOR MODIFICATION; CAREGIVER; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIET; DRUG EFFICACY; HEALTH CARE COST; HUMAN; LIFESTYLE; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; REVIEW;

EID: 33745586537     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.6.3.315     Document Type: Review

References (48)

1. American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care 26(3), 917-932 (2003).
2. Rubin RJ, Altman WM, Mendelson DN. Health care expenditures for people with diabetes mellitus, 1992. J. Clin. Endocrinol. Metab. 78(4), 809A-809F (1994).
3. Selby JV, Ray GT, Zhang D, Colby CJ. Excess costs of medical care for patients with diabetes in a managed care population. Diabetes Care 20(9), 1396-1406 (1997).
4. Ramsey S, Summers KH, Leong SA, Birnbaum HG, Kemner JE, Greenberg P. Productivity and medical costs of diabetes in a large employer population. Diabetes Care 25(1), 23-29 (2002).
5. Brown JB, Nichols GA, Glauber HS, Bakst AW. Type 2 diabetes: incremental medical care costs during the first 8 years after diagnosis. Diabetes Care 22(7), 1116-1124 (1999).
6. Hodgson TA, Cohen AJ. Medical care expenditures for diabetes, its chronic complications and its comorbidities. Prev. Med. 29(3), 173-186 (1999).
7. Harris MI. Chapter 1 summary. In: Diabetes in America, 2nd Edition. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIH Pub. No. 95-1468), MD, USA, 1-13 (1995).
8. Harris MI, Zimmet P. Classification of diabetes mellitus and other categories of glucose intolerance. In: International Textbook of Diabetes Mellitus, 2nd Edition. John Wiley & Sons, NY, USA, 13-16 (1997).
9. Pinhas-Hamiel O, Dolan LM, Daniels SR, Staniford D, Khoury P, Zeitler P. Increased incidence of non-inuslin-dependent diabetes mellitus among adolescents. J. Pediatr. 128, 608-615 (1996).
10. Libman IM, LaPorte RE, Becker D, Dorman JS, Drash AL, Kuller L. Was there an epidemic of diabetes in nonwhite adolescents in Allegheny County, Pennsylvania? Diabetes Care 21(8), 1278-1281 (1998).
11. Neufield ND, Raffel LJ, Landon C, Chen YD, Vadheim CM. Early presentation of type 2 diabetes in Mexican-American youth. Diabetes Care 21, 80-86 (1998).
12. Savage PJ, Bennett PH, Senter G, Miller M. High prevalence of diabetes in young Pima Indians: evidence of phenotypic variation and in a genetically isolated population. Diabetes 28, 837-842 (1979).
13. Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. J. Pediatr. 146(5), 693-700 (2005).
14. Blackburn GL. Effect of degree of weight loss on health benefits. Obes. Res. 3, 211S-216S (1995).
15. Goldstein DJ. Beneficial health effects of modest weight loss. Int. J. Obes. 16, 397-415 (1992).
16. Wing RR, Koeske R, Epstein LH, Nowalk MP Gooding W, Becker D. Long-term effects of modest weight loss in type 2 diabetic patients. Arch. Intern. Med. 147, 1749-1753 (1987).
17. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393-403 (2002).
18. Furlong WJ, Feeny DH, Torrance GW, Barr RD. The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies. Ann. Med. 33, 375-384 (2001).
19. Gray A, Raikou M, McGuire A et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group. Br. Med. J. 320(7246), 1373-1378 (2000).
20. Clarke P, Gray A, Adler A et al. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51). Diabetologja 44(3), 298-304 (2001).
21. Gray A, Clarke P, Raikou M et al. An economic evaluation of atenolol vs captopril in patients with Type 2 diabetes (UKPDS 54). Diabet. Med. 18(6), 438-444 (2001).
22. Clarke PM, Gray AM, Briggs A, Stevens RJ, Matthews DR, Holman RR; on behalf of the UK Prospective Diabetes Study (UKPDS). Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia 48(5), 868-877 (2005).
23. The Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. JAMA 276(17), 1409-1415 (1996).
24. Dong FB, Sorensen SW, Manninen DL et al. Cost effectiveness of ACE inhibitor treatment for patients with type 1 diabetes mellitus. Pharmacoeconomics 22(15), 1015-1027 (2004).
25. Hoerger TJ, Harris R, Hicks KA, Donahue K, Sorensen S, Engelgau M. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Ann. Intern. Med. 140(9), 689-699 (2004).
26. Herman WH, Hoerger TJ, Brandle M et al.; Diabetes Prevention Program Research Group. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann. Intern. Med. 142(5), 323-332 (2005).
27. Epstein LH, Myers MD, Raynor HA, Saelens BE. Treatment of pediatric obesity. Pediatrics 101(3), 554-570 (1998).
28. Epstein LH, Squires S. ne Stoplight Diet for Children: An Eight-week Program for Parents and Children. Little, Brown and Company, MA, USA (1998).
29. Faith MS, Saelens BE, Wilfley DE, Allison DB. Behavioral treatment of childhood and adolescent obesity: current status, challenges, and future directions. In: Body Image, Eating Disorders, and Obesity in Youth: Assessment, Prevention, and Treatment. Thompson JK, Smolak L (Eds), American Psychological Association, Washington DC, USA, 313-340 (2001).
30. Goldfield GS, Epstein LH. Management of obesity in children. In: Eating Disorders and Obesity, 2nd Edition. Fairburn CG, Brownell KD (Eds), Guilford Press, NY, USA, 573-577 (2002).
31. Epstein LH, Klein KR, Wisniewski L. Child and parent factors that influence psychological problems in obese children. Int. J. Eat. Disord. 15, 151-158 (1994).
32. Golan M, Weizman A, Apter A, Fainaru M. Parents as the exclusive agents of change in the treatment of childhood obesity. Am. J. Clin. Nutr: 67, 1130-1135 (1998).
33. Finkelstein EA, Rubin CJ, Kosa KM. Economic causes and consequences of obesity. Annu. Rev. Public Health 26, 239-257 (2005).
34. Drewnowski A. Obesity and the food environment, dietary energy density and diet costs. Am. J. Prev. Med. 27(3S), 154-162 (2004).
35. Philipson T, Dai C, Helmchen L, Variyam JN. The economics of obesity, a report on the workshop held at USDA's Economic Research Service. Pub. No. E-FAN-04-004. US Dept. of Agriculture, Economic Research Service (2004).
36. French SA, Story M, Jeffery RW. Environmental influences on eating and physical activity. Annu. Rev. Public Health 22, 309-335 (2001).
37. Chou SY, Grossman M, Saffer H. An economic analysis of adult obesity; results from the behavioral risk factor surveillance system. In: The Economics of Obesity. Pub. No. E-FAN-04-004, Dept. of Agriculture, Economic Research Service (2004).
38. Kimm SYS, Glynn NW, Kriska AM et al. Longitudinal changes in physical activity in a biracial cohort during adolescence. Med Sci. Sports Exerc. 32, 1445-1454 (2000).
39. Coditz GA, Willett WC, Stampfer MJ et al. Weight as a risk factor for clinical diabetes in women. Am. J. Epidemiol. 132, 501-513 (1990).
40. Manson JE, Rimm EB, Stampfer MJ et al. Physical activity and incidence of non-insulin-dependent mellitus in women. Lancet 338, 774-778 (1991).
41. Frank LD. Economic determinants of urban form, resulting trade-offs between active and sedentary forms of travel. Am. J. Prev. Med. 27(3S), 146-153 (2004).
42. Sturm R. The economic of physical activity, societal trends and rationales for interventions. Am. J. Prev. Med. 27(3S), 126-135 (2004).
43. Raynor HA, Kilanowski CK, Esterlis I, Epstein LH. A cost-analysis of adopting a healthful diet in a family-based obesity treatment program. J. Am. Diet. Assoc. 102(5), 645-656 (2002).
44. Reed J, Frazao, E, Itskowitz R. How much do Americans pay for fruits and vegetables? Agricultural Information Bulletin No. AIB790, US Dept. of Agriculture, Economic Research Service (2004).
45. Blisard N. Food spending in American households, 1997-98. ERS Statistical Bulletin No. 972. US Dept. of Agriculture, Economic Research Service (2001).
46. Forshee RA. Methods of surveying diet and physical activity. In: Tne Economics of Obesity. Pub. No. E-FAN-04-004, US Dept. of Agriculture, Economic Research Service (2004).
47. Torti FM Jr, Gwyther LP, Reed SD, Friedman JY, Schulman KA. A multinational review of recent trends and reports in dementia caregiver burden. Alzheimer Dis. Assoc. Disord. 18(2), 99-109 (2004).
48. Sturm R. Economics and physical activity, a research agenda. Am. J. Prev. Med. 28(2 Suppl. 2), 141-149 (2005).